Ignota Labs

Ignota Labs is a Cambridge, UK-based company that acquires or in-licenses small-molecule drug programmes that stalled or were abandoned because of safety and toxicity findings, re-engineers them, and advances them back through development. Its platform, SAFEPATH, applies deep learning to combined cheminformatics and bioinformatics datasets to explain why a toxicity occurred and how it might be mitigated, rather than only identifying what went wrong in preclinical or clinical safety assessments. The company frames drug failure data as an underused resource, citing that more than half of small molecules entering preclinical trials fail on safety grounds and that safety failures cost the pharmaceutical industry over $400 billion annually.

The operating model has three stages: identifying and assessing failed or shelved assets at scale; solving the safety problem through new chemistry and IP that also generates fresh intellectual property; and developing the asset to a key inflection point before selling or partnering it. Programmes are typically picked up at points where they are, in the company's characterisation, 80–90% of the way to success. The disclosed pipeline includes lanraplenib, a SYK inhibitor for immune thrombocytopenia and warm autoimmune hemolytic anemia whose prior Phase 2 trials did not succeed; a PDE9 inhibitor for kidney and cardio-metabolic disease that previously encountered genotoxicity at candidate selection; a CDK9 inhibitor for acute myeloid leukemia acquired at Phase 2 after neurotoxicity emerged, where the strategy is to reduce brain penetration and optimise pharmacokinetics; and an undisclosed target in blood cancers and solid tumours, plus further assets identified for potential acquisition.

The company was founded by CEO Sam Windsor, who previously worked on DeepMind's AlphaFold team, Chief Scientific Officer Jordan Lane, who has advanced five assets to clinical development, and Chief Data Science Officer Layla Hosseini-Gerami, who specialises in AI and cheminformatics.

Founding story

The company was founded by a multidisciplinary team spanning machine learning, drug discovery, and drug development and commercialisation: Sam Windsor (CEO), previously on DeepMind's AlphaFold team and with a decade of life sciences experience; Jordan Lane (Chief Scientific Officer); and Layla Hosseini-Gerami (Chief Data Science Officer).

Business model

Ignota Labs builds a pipeline by acquiring or in-licensing distressed drug assets, resolving their safety liabilities with SAFEPATH and new chemistry, and creating new intellectual property. Assets are developed to a key inflection point and then sold or partnered, and the company also states it partners and co-develops assets with others.

Value is intended to be realised by selling or partnering turned-around assets after development to an inflection point, and through partnership and co-development arrangements.

Traction

By February 2025 the company said it had in-licensed its first asset, a first-in-class metabolic health drug, and used SAFEPATH to resolve the safety concerns that had halted it, validating findings in rodent models. In October 2025 it acquired Kronos's clinical pipeline. Its disclosed pipeline covers four programmes plus additional identified assets. Recognition includes winning at the Royal Society of Chemistry Emerging Technologies Competition 2024, Sanofi's iDEA-Tech Award, selection among ten winners of an AI for Science Datasets RFP, and a Highly Commended placing for AI Company of the Year; it established a scientific advisory board in August 2026.

Latest developments

Recent company news includes the establishment of a scientific advisory board (August 2026), research on multimodal cheminformatic and network biology analysis of PFAS-induced hepatotoxicity (July 2026), a Nature piece by the company on using AI to turn failed drugs into new medicines (June 2026), selection among ten winners of the AI for Science Datasets RFP (April 2026), a Highly Commended placing for AI Company of the Year (May 2026), and the appointment of Jordan Lane to the UK Young Academy (March 2026).